Fundraising Fox
Fogpharma
Boston, US · Founded 2015 · 201 employees on LinkedIn · 4 known investors
Find your way into Fogpharma
Each arrow is one introduction. Sign up to fill in the first one.
Ask Eric d'Esparbes to introduce you to Mathai Mammen
You →Eric · together at Innoviva →Mathai
Sign up to find every way you can get introduced to Fogpharma
- Your email: who you already know at Fogpharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Fogpharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases. The company operates a custom-built research platform focused on this peptide modality for drug discovery.
Founders & leadership
Fogpharma was founded in 2015 by Gregory L Verdine.
Investors · 4
Reported raises · per SEC filings
Form D private placements$278.4M disclosed across 5 rounds · 2015–2022
▶$178MraisedDec 2022 · 24 investors · PharmaceuticalsRule 506(b)
- WeiQing ZhouExecutive Officer
- Corey S. GoodmanDirector
- Krishna YeshwantDirector
- Rick KlausnerDirector
- Jeffrey A. LeerinkDirector
- Edward M. FitzgeraldDirector
- Barbara WeberDirector
- Gregory L. VerdineExecutive Officer, Director
- Offering amount
- $178M
- Amount sold
- $178M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.3MraisedJan 2021 · 22 investors · PharmaceuticalsRule 506(b)
- Barbara WeberDirector
- Krishna YeshwantDirector
- Leon ChenDirector
- Edward M. FitzgeraldDirector
- Jeffrey A. LeerinkDirector
- Gregory L. VerdineExecutive Officer, Director
- WeiQing ZhouExecutive Officer
- Offering amount
- $107M
- Amount sold
- $23.3M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$65.5MraisedMay 2018 · 24 investors · PharmaceuticalsRule 506(b)
- Leon ChenDirector
- WeiQing ZhouExecutive Officer
- Jeffrey A. LeerinkDirector
- Edward FitzgeraldDirector
- Gregory L. VerdineExecutive Officer, Director
- Offering amount
- $66M
- Amount sold
- $65.5M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$11MraisedAug 2017 · 13 investors · PharmaceuticalsRule 506(b)
- Jeffrey A LeerinkDirector
- Edward M FitzgeraldDirector
- WeiQing ZhouExecutive Officer
- Gregory L VerdineExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $11M
- Proceeds to insiders
- $1.1M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$625KraisedNov 2015 · 4 investors · PharmaceuticalsRule 506(b)
- Gregory L VerdineExecutive Officer, Director
- Amount sold
- $625K
- Proceeds to insiders
- $125K
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Fogpharma do?
- FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases. The company operates a custom-built research platform focused on this peptide modality for drug discovery.
- Who founded Fogpharma?
- Fogpharma was founded by Gregory L Verdine in 2015.
- Who are Fogpharma's investors?
- Fogpharma's investors include Catalio Capital Management, LP, Horizons Ventures, GV (Google Ventures), venBio Global Strategic.
- How much funding has Fogpharma raised?
- Fogpharma has disclosed $278.4M raised across 5 rounds.
- Where is Fogpharma headquartered?
- Fogpharma is headquartered in Boston, US.